<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, May 19, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/reports/2190608/infectious_diseases_collaboration_and_licensing?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=4mfn66&amp;utm_campaign=2255909+-+Infectious+Diseases+Collaboration+and+Licensing+Agreements+Benchmark+Report+2026%3a+Access+to+1%2c700%2b+Real-world+Partnerships+Across+Vaccines%2c+Antivirals%2c+Antibiotics%2c+and+Emerging+Technologies&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="Infectious Diseases Collaboration and Licensing Deals 2020-2026">"Infectious Diseases Collaboration and Licensing Deals 2020-2026"</a> report has been added to ResearchAndMarkets.com's offering. This report gives you direct access to 1,700+ real-world partnerships, so you can see exactly how deals are structured, valued, and negotiated across vaccines, antivirals, antibiotics, and emerging technologies. Infectious Diseases Collaboration and Licensing Deals <ul><li>Stop guessing.</li><li>Start benchmarking real deals.</li><li>If you're working on an infectious disease deal, you don't need more opinions - you need evidence.</li><li>Know what a "good deal" actually looks like</li><li>Without real benchmarks, you're negotiating in the dark.</li></ul> With this report, you can: <ul><li>Anchor negotiations with real precedent</li><li>See what companies are actually paying - not what they claim in press releases</li><li>Benchmark deal terms instantly</li><li>Compare upfronts, milestones, and royalty structures across relevant transactions</li><li>Avoid overpaying or underselling</li><li>Understand the realistic range for deals at your stage and in your space</li><li>Challenge counterpart assumptions with data</li><li>Walk into negotiations backed by hard evidence, not guesswork</li><li>See how deals are really written - not just announced</li></ul> Most datasets stop at headlines. That's not enough. This report gives you access to actual contracts, so you can see: <ul><li>How rights are allocated</li><li>What partners commit to (and what they don't)</li><li>How payments are structured and triggered</li><li>Where risks and flexibilities sit</li></ul> This is the detail that defines deal outcomes - and it's usually hidden. <ul><li>Built for teams actively doing deals</li></ul> Whether you're licensing, partnering, or evaluating opportunities, this report helps you: <ul><li>Move faster with immediate access to relevant comparables</li><li>De-risk decisions using real transaction evidence</li><li>Strengthen internal alignment with credible market data</li><li>Negotiate from a position of strength</li></ul> What you get <ul><li>1,700+ infectious disease deals</li><li>Financial terms, including royalties where disclosed</li><li>Fully searchable deal database (by company, therapy, technology, stage)</li><li>Direct access to SEC-filed agreements</li><li>850+ pages of structured deal analysis</li><li>The bottom line</li></ul> If you're making decisions on incomplete information, you're taking unnecessary risk. This report gives you the data, benchmarks, and contract-level insight to structure better deals - and win them. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in infectious diseases dealmaking 2.1. Introduction 2.2. Infectious diseases partnering over the years 2.3. Infectious diseases partnering by deal type 2.4. Infectious diseases partnering by industry sector 2.5. Infectious diseases partnering by stage of development 2.6. Infectious diseases partnering by technology type 2.7. Infectious diseases partnering by therapeutic indication Chapter 3 - Financial deal terms for infectious diseases partnering 3.1. Introduction 3.2. Disclosed financials terms for infectious diseases partnering 3.3. Infectious diseases partnering headline values 3.4. Infectious diseases deal upfront payments 3.5. Infectious diseases deal milestone payments 3.6. Infectious diseases royalty rates Chapter 4 - Leading infectious diseases deals and dealmakers 4.1. Introduction 4.2. Most active in infectious diseases partnering 4.3. List of most active dealmakers in infectious diseases 4.4. Top infectious diseases deals by value Chapter 5 - Infectious diseases contract document directory 5.1. Introduction 5.2. Infectious diseases partnering deals where contract document available Chapter 6 - Infectious diseases dealmaking by therapeutic target 6.1. Introduction 6.2. Deals by infectious diseases therapeutic target Deal directory <ul><li>Deal directory - Infectious diseases deals by company A-Z</li><li>Deal directory - Infectious diseases deals by technology type</li><li>Deal type definitions</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/2190608/infectious_diseases_collaboration_and_licensing?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=4mfn66&amp;utm_campaign=2255909+-+Infectious+Diseases+Collaboration+and+Licensing+Agreements+Benchmark+Report+2026%3a+Access+to+1%2c700%2b+Real-world+Partnerships+Across+Vaccines%2c+Antivirals%2c+Antibiotics%2c+and+Emerging+Technologies&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/xx5yz8</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/YmJlMDFiMGQtNGM3Yi00ZTE5LThkMzItOTI4ODkwMDM3ZGIwLTEwMjY3MzctMjAyNi0wNS0xOS1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Infectious Diseases Collaboration and Licensing Agreements Benchmark Report 2026: Access to 1,700+ Real-world Partnerships Across Vaccines, Antivirals, Antibiotics, and Emerging Technologies

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn